Given the growing evidence and interest in the impact of cancer metabolism in disease aggressiveness, it is imperative to further understand the regulatory mechanisms responsible for of LAT1 and ASCT2 modulation in CRC and study the potential of their inhibition as a therapeutic approach. Here, SLC1A5 is linked to colorectal carcinoma.